Comparative Pharmacology
Head-to-head clinical analysis: TERRAMYCIN versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TERRAMYCIN versus TETREX.
TERRAMYCIN vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg orally every 6 hours or 1-2 g intravenously every 12 hours. Maximum oral dose: 2 g/day.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 8-10 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (creatinine clearance <10 mL/min).
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal (primarily glomerular filtration, 20-60% unchanged in urine), biliary/fecal (10-30% via bile into feces).
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic